- Conditions
- Human Papillomavirus (HPV)-Related Malignancies, Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
- Interventions
- Ribavirin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 3,690
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Wheezing, Asthma in Children
- Interventions
- Soy isoflavone, matching placebo
- Drug
- Lead sponsor
- Rajesh Kumar
- Other
- Eligibility
- 2 Months to 12 Months
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Hereditary Inclusion Body Myopathy (HIBM)
- Interventions
- Sialic Acid Extended Release (SA-ER) Tablets, Sialic Acid Extended Release (SA-ER) Tables
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Costa Mesa, California • New York, New York
- Conditions
- Newly Diagnosed Glioblastoma Multiforme
- Interventions
- Lapatinib/Temozolomide/radiation
- Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Sinemet, IPX203
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Boca Raton, Florida • Naples, Florida + 7 more
- Conditions
- Metastatic Melanoma
- Interventions
- RO6874281, Pembrolizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Iowa City, Iowa • Boston, Massachusetts
- Conditions
- Malignant Solid Tumor, Childhood Solid Tumor
- Interventions
- Sirolimus, Cyclophosphamide, Topotecan
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Smoking Cessation
- Interventions
- Zonisamide, Bupropion, Halo G6 e-cigarette
- Drug · Other
- Lead sponsor
- Rose Research Center, LLC
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Raleigh, North Carolina
- Conditions
- Schizophrenia
- Interventions
- ALKS 3831, Olanzapine
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 52
- States / cities
- Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 46 more
- Conditions
- Antifungal Drug Adverse Reaction
- Interventions
- NES/EE CVR
- Drug
- Lead sponsor
- Population Council
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Metastatic Lung Cancer, NSCLC
- Interventions
- nivolumab and ablation
- Drug
- Lead sponsor
- howard safran
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Providence, Rhode Island
- Conditions
- Kaposi Sarcoma
- Interventions
- Propranolol Hydrochloride
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Autism Spectrum Disorder, Repetitive Compulsive Behavior
- Interventions
- amitriptyline
- Drug
- Lead sponsor
- University of Missouri, Kansas City
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Constipation, Surgical Procedure, Unspecified, Prolapse; Female
- Interventions
- Polyethylene Glycol 3350
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years to 89 Years · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lupus Nephritis
- Interventions
- Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 28
- States / cities
- Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more
- Conditions
- Healthy, Drug Drug Interaction
- Interventions
- Itraconazole, Rifampin, KBP-5074
- Drug
- Lead sponsor
- KBP Biosciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Sickle Cell Disease, Thalassemia, Beta, Thalassemia
- Interventions
- Fludarabine, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Rabbit ATG, Dexamethasone, Bortezomib, Rituximab
- Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 2 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
- Conditions
- NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Neurofibromatosis Type 1 (NF1)
- Interventions
- PAS-004 Tablets
- Drug
- Lead sponsor
- Pasithea Therapeutics Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Newly Diagnosed Glioblastoma
- Interventions
- Nivolumab, Relatlimab, TMZ, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- New York, New York • Durham, North Carolina • Houston, Texas
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Interventions
- filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Seattle, Washington
- Conditions
- Advanced Cancer, Solid Tumors, Cancer, Neoplasms
- Interventions
- rigosertib sodium
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- Alvimopan, Placebo
- Drug
- Lead sponsor
- Jamie N. Bakkum-Gamez
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Smoking Cessation
- Interventions
- Varenicline
- Drug
- Lead sponsor
- Nikki Nollen, PhD, MA
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Kansas City, Missouri
- Conditions
- GVHD - Graft-Versus-Host Disease
- Interventions
- Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York